ARDELYX, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARDELYX, INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was -$12.00K, a 100.06% decline year-over-year.
- ARDELYX, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $57.16M, a 66.33% increase year-over-year.
- ARDELYX, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $11.37M, a 9.48% decline year-over-year.
- ARDELYX, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $50.72M, a 756.60% increase year-over-year.
- ARDELYX, INC. stock issued during period, value, new issues for fiscal 2023 was $119.24M, a 66.47% increase from fiscal 2022.
- ARDELYX, INC. stock issued during period, value, new issues for fiscal 2022 was $71.63M, a 29.19% decline from fiscal 2021.
- ARDELYX, INC. stock issued during period, value, new issues for fiscal 2021 was $101.15M, a 380.57% increase from fiscal 2020.
- ARDELYX, INC. stock issued during period, value, new issues for fiscal 2020 was $21.05M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $119.24M 10-K · filed 2026-02-19 |
| 2023-09-30 | $57.16M 10-Q · filed 2024-10-31 | $138.03M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $11.37M 10-Q · filed 2024-08-01 | $115.23M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $50.72M 10-Q · filed 2024-05-02 | $116.42M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $18.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $71.63M 10-K · filed 2025-02-20 |
| 2022-09-30 | $34.37M 10-Q · filed 2023-10-31 | $86.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $12.56M 10-Q · filed 2023-08-02 | $57.18M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $5.92M 10-Q · filed 2023-05-03 | $72.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $33.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $101.15M 10-K · filed 2024-02-22 |
| 2021-09-30 | $4.74M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $28.17M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $34.27M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $21.05M 10-K · filed 2023-03-02 | |
| 2014-12-31 | $61.24M 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |